Tiger Brokers

Artelo Biosciences expands ART27.13 into glaucoma via fully funded investigator-sponsored clinical study; glaucoma market totals $16.3 billion

Reuters
Mar 25
<a href="https://laohu8.com/S/ARTL">Artelo Biosciences</a> expands ART27.13 into glaucoma via fully funded investigator-sponsored clinical study; glaucoma market totals $16.3 billion
  • Artelo Biosciences announced an expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study of ART27.13, with study costs funded by Glaucoma UK and the HSC R&D Division.
  • The company said it retains full data rights under the investigator-sponsored trial structure.
  • Positive interim Phase 2 data for ART27.13 in cancer anorexia cachexia were already presented at the 17th International Conference on Sarcopenia, Cachexia & Wasting Disorders by Professor Barry J.A. Laird.
  • Artelo Biosciences said ART26.12 completed a first-in-human Phase 1 single-ascending-dose study in 2025, with enrollment being prepared for a multiple ascending dose study in Q3 2026.
  • The company said first-in-human studies for ART12.11 are planned for the first half of 2026 following UK MHRA guidance supporting streamlined Phase 1 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250731PRIMZONEFULLFEED9678238) on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10